Medgenics (MDGN) Gets Allowance for Key European Patent

Medgenics Inc - MDGN - reported that it has received notice of ‘Intention to Grant’ from the European Patent Office for the patent application end “USE OF DERMAL MICRO ORGANS,” with allowed claims covering a core e...

Medgenics Inc - MDGN - reported that it has received notice of
‘Intention to Grant’ from the European Patent Office for the
patent application end “USE OF DERMAL MICRO ORGANS,” with
allowed claims covering a core element of its Biopump protein
therapy technology. This follows Similar U.S. Patent for Biopump
Protein Therapy Technology and Expands Medgenics’ Intellectual
Property Portfolio. Medgenics is developing and commercializing
Biopump, a proprietary tissue-based platform technology for the
sustained production and delivery of therapeutic proteins using the
patient’s own skin biopsy for the treatment of a range of chronic
diseases including anemia, hepatitis C and
hemophilia.

*********************************

THIS IS NOT A
RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at
http//www.crwenewswire.com/disclaimer)